Investigational drug · Phase 2
CU01-1001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetic Nephropathies.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "CU01-1001"
First trial start
2023
Feb 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CU01-1001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Nephropathies
Approved drugs for the same conditions: Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "CU01-1001" as an intervention, largest first.
- Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With AlbuminuriaPivotal-lookingCompleted
Curacle Co., Ltd.Industry
NCT05718375 · 240 participants · Start Feb 14, 2023 · Primary completion Nov 12, 2025
Drug: CU01-1001; Placebo · For: Diabetic Nephropathies
Sites: Busan, South Korea; Chuncheon, South Korea; Daegu, South Korea · 24 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diabetic Nephropathies
- WAL0921Phase 21 trial
Walden Biosciences · Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.